EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head‐and‐neck dermatitis

Ida Vittrup iD, Niels Steen Krogh iD, Henrik Hedegaard Pliess Larsen, Jesper Elberling iD, Lone Skov iD, Kristina Sophie Ibler iD, Gregor B E Jemec iD, Charlotte G Mortz iD, Rasmus Overgaard Bach iD, Carsten Bindslev-Jensen iD, Maiken Glud Dalager, Alexander Egeberg iD und 4 weitere

Journal of the European Academy of Dermatology and Venereology · 2023-05 · 37 (5) · 1046-1055

DOI: 10.1111/jdv.18849 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 21.01.2023. Verfasst von Ida Vittrup und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Conjunctivitis. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer, Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evaluation of effectiveness and safety of new systemic treatments for atopic dermatitis (AD) after approval is important. There are few published data exceeding 52‐week therapy with dupilumab.

Objectives

To examine the safety, effectiveness and drug survival of dupilumab in a Danish nationwide cohort with moderate‐to‐severe AD up to 104 weeks exposure.

Methods

We included 347 adult patients with AD who were treated with dupilumab and registered in the SCRATCH registry during 2017–2022.

Results

At all visits, we observed improvement in AD severity measured by Eczema Area and Severity Index (EASI) [median (IQR)]. EASI score at baseline was 18.0 (10.6–25.2), at week 4: 6.5 (3.5–11.6), at week 16: 3.7 (1.2–6.2), at week 52: 2.0 (0.8–3.6), at week 104: 1.7 (0.8–3.8). While drug survival was high (week 52: 90%; week 104: 86%), AD in the head‐and‐neck area remained present in most patients at high levels; proportion with head‐and‐neck AD at baseline was 76% and 68% at week 104. 35% of patients reported any AE. Conjunctivitis was the most frequent (25% of all patients) and median time to first registration of conjunctivitis was 201 days.

Conclusions

While 2‐year drug survival was 86%, dupilumab was unable to effectively treat AD in the head‐and‐neck area, and conjunctivitis was found in 25% of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicConjunctivitisHumansAdultInjections, SubcutaneousTreatment OutcomeSeverity of Illness IndexDouble-Blind MethodAntibodies, Monoclonal, Humanized

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.
  • ZiteLab ApS, Frederiksberg, Denmark.
  • Department of Dermatology, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark.
  • Department of Dermatology and Allergy Center, Odense University Hospital, Odense, Denmark.
  • Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark.

ORCID-Profile: Ida Vittrup, Niels Steen Krogh, Jesper Elberling, Lone Skov, Kristina Sophie Ibler, Gregor B E Jemec, Charlotte G Mortz, Rasmus Overgaard Bach, Carsten Bindslev-Jensen, Alexander Egeberg, Tove Agner, Mette Deleuran, Christian Vestergaard, Jacob Pontoppidan Thyssen

Förderung

  • Pfizer
  • Sanofi

Zitieren

APA

Vittrup, I., Krogh, N. S., Larsen, H. H. P., Elberling, J., Skov, L., Ibler, K. S., Jemec, G. B. E., Mortz, C. G., Bach, R. O., Bindslev-Jensen, C., Dalager, M. G., Egeberg, A., Agner, T., Deleuran, M., Vestergaard, C., & Thyssen, J. P. (2023). A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head‐and‐neck dermatitis. Journal of the European Academy of Dermatology and Venereology, 37(5), 1046-1055. https://doi.org/10.1111/jdv.18849

Vancouver

Vittrup I, Krogh NS, Larsen HHP, Elberling J, Skov L, Ibler KS, et al. A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head‐and‐neck dermatitis. Journal of the European Academy of Dermatology and Venereology. 2023;37(5):1046-1055. doi:10.1111/jdv.18849

BibTeX
@article{Vittrup2023,
  author = {Vittrup, Ida and Krogh, Niels Steen and Larsen, Henrik Hedegaard Pliess and Elberling, Jesper and Skov, Lone and Ibler, Kristina Sophie and Jemec, Gregor B E and Mortz, Charlotte G and Bach, Rasmus Overgaard and Bindslev-Jensen, Carsten and Dalager, Maiken Glud and Egeberg, Alexander and Agner, Tove and Deleuran, Mette and Vestergaard, Christian and Thyssen, Jacob Pontoppidan},
  title = {A nationwide 104 weeks real‐world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head‐and‐neck dermatitis},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  volume = {37},
  number = {5},
  pages = {1046--1055},
  doi = {10.1111/jdv.18849}
}
Kostenlos starten →